Compare · LMDX vs ORKA
LMDX vs ORKA
Side-by-side comparison of LumiraDx Limited (LMDX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMDX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.55B, about 2.5x LMDX ($2.23B).
- ORKA has hit the wire 4 times in the past 4 weeks while LMDX has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 4 for LMDX).
- Company
- LumiraDx Limited
- Oruka Therapeutics Inc.
- Price
- $0.02-53.80%
- $91.93-0.66%
- Market cap
- $2.23B
- $5.55B
- 1M return
- -
- +10.21%
- 1Y return
- -
- +546.94%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 4
- 11
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)